These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 10466959)

  • 1. Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys.
    Raengsakulrach B; Nisalak A; Gettayacamin M; Thirawuth V; Young GD; Myint KS; Ferguson LM; Hoke CH; Innis BL; Vaughn DW
    Am J Trop Med Hyg; 1999 Mar; 60(3):343-9. PubMed ID: 10466959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intranasal challenge model for testing Japanese encephalitis vaccines in rhesus monkeys.
    Raengsakulrach B; Nisalak A; Gettayacamin M; Thirawuth V; Young GD; Myint KS; Ferguson LM; Hoke CH; Innis BL; Vaughn DW
    Am J Trop Med Hyg; 1999 Mar; 60(3):329-37. PubMed ID: 10466957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
    Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE
    Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice.
    Konishi E; Kurane I; Mason PW; Shope RE; Ennis FA
    Virology; 1997 Jan; 227(2):353-60. PubMed ID: 9018134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Japanese encephalitis virus DNA vaccine candidates in rhesus monkeys [Macaca mulatta].
    Bharati K; Rani R; Vrati S
    Vaccine; 2009 Jan; 27(1):10-6. PubMed ID: 18996161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
    Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
    J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates.
    Konishi E; Kurane I; Mason PW; Shope RE; Kanesa-Thasan N; Smucny JJ; Hoke CH; Ennis FA
    Vaccine; 1998 May; 16(8):842-9. PubMed ID: 9627942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines.
    Welter J; Taylor J; Tartaglia J; Paoletti E; Stephensen CB
    J Virol; 2000 Jul; 74(14):6358-67. PubMed ID: 10864646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine.
    Konishi E; Pincus S; Paoletti E; Laegreid WW; Shope RE; Mason PW
    Virology; 1992 Sep; 190(1):454-8. PubMed ID: 1326813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.
    Markoff L
    Vaccine; 2000 May; 18 Suppl 2():26-32. PubMed ID: 10821970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals.
    Bielefeldt-Ohmann H; Prow NA; Wang W; Tan CS; Coyle M; Douma A; Hobson-Peters J; Kidd L; Hall RA; Petrovsky N
    Vet Res; 2014 Dec; 45(1):130. PubMed ID: 25516480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and Immunogenicity of Recombinant Vaccinia Virus Vaccine Against Japanese Encephalitis and Chikungunya Viruses Infection in Mice.
    Zhang Y; Han JC; Jing J; Liu H; Zhang H; Li ZH; Jin NY; Lu HJ
    Vector Borne Zoonotic Dis; 2020 Oct; 20(10):788-796. PubMed ID: 32584657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein.
    Jan LR; Yang CS; Henchal LS; Sumiyoshi H; Summers PL; Dubois DR; Lai CJ
    Am J Trop Med Hyg; 1993 Mar; 48(3):412-23. PubMed ID: 8385887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
    Cao L; Fu S; Gao X; Li M; Cui S; Li X; Cao Y; Lei W; Lu Z; He Y; Wang H; Yan J; Gao GF; Liang G
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004686. PubMed ID: 27139722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of swine by potent neutralizing anti-Japanese encephalitis virus monoclonal antibodies derived from vaccination.
    Young CL; Lyons AC; Hsu WW; Vanlandingham DL; Park SL; Bilyeu AN; Ayers VB; Hettenbach SM; Zelenka AM; Cool KR; Peterson GJ; Higgs S; Huang YS
    Antiviral Res; 2020 Feb; 174():104675. PubMed ID: 31825852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.